Edwards Lifesciences exec exercises options, sells shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related stock sale. He exercised 619 Employee Stock Options at an exercise price of $72.68 per share, receiving 619 shares of Common Stock, and then sold 619 shares of Common Stock at $92.03 per share. Following the option exercise, he reported holding 4,333 options for Common Stock. The equity trades referencing the plan were effected pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 619 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 619 | $72.68 | $45K |
| Sale | Common Stock F1 | 619 | $92.03 | $57K |
Footnotes (1)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Employee Stock Option financial
Exercise or conversion of derivative security financial
beneficial ownership financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Edwards Lifesciences (EW) report for Daniel J. Lippis?
How many options does Daniel J. Lippis retain after this Form 4 at Edwards Lifesciences (EW)?
Were the Edwards Lifesciences (EW) insider trades by Daniel J. Lippis under a Rule 10b5-1 plan?
What role does Daniel J. Lippis hold at Edwards Lifesciences (EW) in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.